Related Experiment Videos
Clinical experience with anti-EGFR therapy
Anne Fish-Steagall1, Polly Searcy, Rebecca Sipples
1Division of Hematology/Oncology, University of North Carolina at Chapel Hill, 3009 Old Clinic Building, Chapel Hill, NC 27599, USA. afs@med.unc.edu
Seminars in Oncology Nursing
|April 18, 2006
Summary
Anti-epidermal growth factor receptor (EGFR) therapies show significant clinical benefit in metastatic colorectal cancer (CRC), head and neck cancers (SCCHN), and lung cancers (NSCLC). These treatments are manageable and improve patient symptoms, especially in those previously treated.
Area of Science:
- Oncology
- Pharmacology
Background:
- Review of clinical data and studies on anti-epidermal growth factor receptor (EGFR) therapies.
- Focus on applications in metastatic colorectal cancer (CRC), squamous cell carcinoma of the head and neck (SCCHN), and non-small cell lung cancer (NSCLC).
Observation:
- Case studies illustrating the use of anti-EGFR agents in each specified cancer type.
- Analysis of clinical trial outcomes and patient experiences.
Findings:
- Phase II/III trials demonstrate the efficacy of anti-EGFR therapy across CRC, SCCHN, and NSCLC.
- Treatment provides significant clinical benefits, including symptom improvement, particularly in pre-treated patients.
- Adverse events associated with anti-EGFR therapies are generally manageable and do not significantly overlap with chemotherapy or radiotherapy toxicities.
Implications:
- Nurses play a crucial role in advancing the understanding and application of anti-EGFR therapies.
- Encouraging patient participation in ongoing clinical trials for anti-EGFR therapy is vital for future treatment advancements.